Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mission Therapeutics
Mission Therapeutics
Activities:
Manufacturing
Drug Delivery
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Mission Therapeutics announces FDA approval for Phase II trial in acute kidney injury
Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application
Research & Development
Mission paper outlines potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s
The research was the result of collaborative work between Cambridge University, Harvard Medical School and Mission Therapeutics
Finance
Mission appoints Dr Suhail Nurbhai CMO
Dr Nurbhai has more than 25 years of experience in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US
Ingredients
Mission raises $15m and expands relationship with Pfizer
The new capital will support the development of Mission's deubiquitylating enzymes (DUB) platform, as well as growth of its pipeline of DUB inhibitor programmes
Drug Delivery
Dr Nick Edmunds appointed to VP, Head of DUB Discovery
Recruitment
Mission Therapeutics strengthens clinical development team
Recruitment
Mission Therapeutics appoints Dr Bobby Soni to board
Subscribe now